Respiratory Microbiota and Immune Response in CVID
Purpose
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of the respiratory tract. The central hypothesis for this research is that antibody (Ab) deficiency in CVID alters respiratory microbiota and host interactions to drive pulmonary disease.
Condition
- CVID
Eligibility
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Patients with primary antibody deficiency diagnosed by their treating physician - Controls will not have a diagnosis of immunodeficiency of any sort - Male and female patients will be enrolled evenly
Exclusion Criteria
- Patients who self identify as pregnant - Patients with asthma or chronic obstructive pulmonary disease (COPD) that are not well controlled clinically
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Antibody deficient participants | Provider referred patients that have antibody deficiency. | |
| Controls | Patients without antibody deficiency from the allergy and immunology clinic at Boston Medical Center and from healthy volunteers at the BU School of Medicine. |
More Details
- Status
- Completed
- Sponsor
- Boston University